• If you are wondering whether DaVita at around US$109.34 is offering good value right now, you are in the right place to make sense of the current price tag.
• The stock is up 1.1% over the last 7 days, while returns over 30 days, year to date, 1 year, 3 years and 5 years, at 3.8% decline, 4.5% decline, 37.9% decline, 27.9% gain and 0.1% gain respectively, paint a mixed picture that can shift how investors think about its risk and reward profile.
• Recent coverage of DaVita has focused on its role in the US healthcare sector and how investors are reassessing dialysis providers in light of evolving treatment patterns and policy attention on chronic kidney care. This context has shaped how the market has been viewing dialysis operators as longer term healthcare infrastructure rather than short term trading stories.
• On our checks, DaVita scores a full 6 out of 6 on valuation. Next, we will walk through the standard valuation tools investors use, then finish with a way to piece them together that can give you a clearer picture of what the stock may be worth.

Approach 1: DaVita Discounted Cash Flow (DCF) Analysis

A DCF model takes the cash DaVita is expected to generate in the future, then discounts those cash flows back into today’s dollars to arrive at an estimate of what the shares might be worth now.

DaVita’s latest twelve month Free Cash Flow is about $1.28b. The model used here is a 2 Stage Free Cash Flow to Equity approach, which starts with explicit projections and then tapers growth in a second stage. For example, Simply Wall St has projected Free Cash Flow of $1,068m for 2025 and then extrapolated annual figures out to 2035, with projected Free Cash Flow of about $1,522.9m in ten years, using modest estimated changes each year.

Discounting those projected cash flows back to today produces an estimated intrinsic value of $318.18 per share. Compared with the recent share price of about $109.34, this DCF output suggests the shares are around 65.6% undervalued according to this methodology.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DaVita is undervalued by 65.6%. Track this in your watchlist or portfolio, or discover 868 more undervalued stocks based on cash flows.

Approach 2: DaVita Price vs Earnings

For a profitable company like DaVita, the P/E ratio is a useful yardstick because it links what you pay for each share to the earnings that share currently generates. Investors usually accept a higher or lower P/E depending on what they expect for future growth and how much risk they see in the business.

DaVita trades on a P/E of about 10.0x. That compares with a Healthcare industry average P/E of about 22.0x and a peer group average of roughly 38.7x. On simple comparisons, the stock sits well below both its industry and peers.

Simply Wall St also calculates a Fair Ratio for DaVita of 21.8x, which is the P/E level suggested by factors such as earnings growth, profit margins, industry, market cap and specific risks. This Fair Ratio can be more tailored than a basic peer or sector comparison because it adjusts for the company’s own characteristics rather than assuming all operators should trade on the same multiple. Lining these up, DaVita’s current P/E of 10.0x is below the 21.8x Fair Ratio, which points to the shares looking undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1417 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your DaVita Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your own story about DaVita, backed by numbers like your assumed fair value and your expectations for future revenue, earnings and margins.

A Narrative connects three things in one place: what you think is happening with the business, how that view translates into a financial forecast and what fair value that forecast implies for the shares.

On Simply Wall St, within the Community page used by millions of investors, Narratives are set up so you can easily see your forecast, compare your Fair Value to the current market price and decide whether that gap suggests DaVita belongs on your watchlist, your buy list or your sell list.

Because Narratives are updated when new information such as earnings reports or major news is added to the platform, your fair value view stays aligned with what is happening in real time instead of being a one off spreadsheet exercise.

For example, one DaVita Narrative might assume a very cautious outlook and arrive at a relatively low fair value, while another assumes stronger operating results and produces a much higher fair value. Yet both investors can see clearly how their stories differ and what that means for their decision on the stock.

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.